{"id":"nebivolol-pill","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL434394","moleculeType":"Small molecule","molecularWeight":"405.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nebivolol blocks beta-1 adrenergic receptors on the heart, decreasing heart rate and contractility to lower blood pressure and reduce cardiac workload. Unlike non-selective beta-blockers, it has additional vasodilatory effects mediated by nitric oxide release in endothelial cells, which may provide additional cardiovascular benefits and improved tolerability.","oneSentence":"Nebivolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and blood pressure while preserving vasodilatory properties through nitric oxide release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:45.573Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT01202175","phase":"PHASE4","title":"Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2010-07","conditions":"Pre-hypertension, Hypertension","enrollment":50},{"nctId":"NCT02467400","phase":"EARLY_PHASE1","title":"Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-07-01","conditions":"Osteoporosis, Age-Related","enrollment":165},{"nctId":"NCT03245996","phase":"PHASE4","title":"The Impact of Heart Rate on Central Blood Pressure in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker","status":"COMPLETED","sponsor":"Tartu University Hospital","startDate":"2015-06","conditions":"Aortic Blood Pressure","enrollment":27},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152},{"nctId":"NCT01939990","phase":"PHASE2, PHASE3","title":"Safety Study of Nebivolol for COPD Patients","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2012-01","conditions":"High Blood Pressure","enrollment":""},{"nctId":"NCT01161823","phase":"","title":"Influence of Nebivolol on Postmenopausal Women","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2010-01","conditions":"Hot Flashes, Heart Rate, Blood Pressure","enrollment":60},{"nctId":"NCT01044693","phase":"NA","title":"Nebivolol in the Supine Hypertension of Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-01","conditions":"Hypertension, Pure Autonomic Failure, Multiple System Atrophy","enrollment":20},{"nctId":"NCT01885988","phase":"PHASE4","title":"Nebivolol Effects on Endothelial Function and Erectile Function","status":"UNKNOWN","sponsor":"Martin M. Miner, MD","startDate":"2013-03","conditions":"Erectile Dysfunction","enrollment":70},{"nctId":"NCT00775671","phase":"PHASE4","title":"Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2008-10","conditions":"Metabolic Syndrome","enrollment":46},{"nctId":"NCT00683124","phase":"PHASE3","title":"Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients","status":"UNKNOWN","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2008-07","conditions":"Marfan Syndrome","enrollment":291}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Nebivolol Pill","genericName":"Nebivolol Pill","companyName":"Tartu University Hospital","companyId":"tartu-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nebivolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and blood pressure while preserving vasodilatory properties through nitric oxide release. Used for Hypertension, Heart failure with reduced ejection fraction, Angina pectoris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}